

OCT. 6. 2004 4:10PM

AVENTIS US PAT DEPT

NO. 8376 P. 7

USA2797 US CNT

RECEIVED
CENTRAL FAX CENTER

OCT 06 2004

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
KLEIN, et al.

Examiner: C. Chang

Art Unit: 1625

Application No.: 10/674,480

Filed: September 30, 2003

Title: **PIPERIDIDINYL AND N-AMIDINOPIPERIDINYL DERIVATIVES**

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, on

October 6, 2004
Date of Transmission

Signature

Preliminary Amendment Pursuant to 37 C.F.R. § 1.115 and
Response to the Restriction Requirement

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

For Office only

This paper is in response to the Office Action dated June 9, 2004 ("the Office Action"), in which a restriction requirement was issued in connection with the above-identified patent application. This paper is also a Preliminary Amendment pursuant to 37 C.F.R. § 115 in connection with the above-identified patent application. Filed concurrently herewith is a Petition for Extension of Time pursuant to 37 C.F.R. § 1.136(a) for three (3) months.

Applicant respectfully request the application be amended, without prejudice, prior to

examination as follows:

OCT. 6. 2004, 4:09PM

AVENTIS US PAT DEPT

RECEIVED
CENTRAL FAX CENTER

NO. 8376 P. 3

OCT 06 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Application of
KLEIN, et al.

Examiner: C. Chang

Application No.: 10/674,480

Art Unit: 1625

Filed: September 30, 2003

Title: **PIPERIDIDINYL AND N-AMIDINOPIPERIDINYL
DERIVATIVES**

TELEFAX CERTIFICATE	
I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, on	
Date of Deposit	October 6, 2004
Printed Name of Person Signing Certificate	Paul Irvine
Signature	<i>Paul Irvine</i>

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Transmitted herewith is an amendment in the above-identified application.

☐ No additional fee is required.

The fee has been calculated as shown below.

(1)	(2) CLAIMS REMAINING AFTER AMENDMENT*	(3)	(4) HIGHEST NUMBER PREVIOUSLY PAID FOR**	(5) PRESENT EXTRA	(6) RATE	(7) ADDITIONAL FEE
TOTAL CLAIMS	35	MINUS	33	2	18.00	36.00
INDEPENDENT CLAIMS	2	MINUS	3	0	86.00	0
MULTI-DEPENDENT CLAIMS(S), Per Application (290.00)						
TOTAL AMENDMENT FEE FOR THIS AMENDMENT →						36.00

- * If the entry in Column 2 is less than the entry in Column 4, write "0" in Column 5.
- ** If the "Highest Number Previously Paid For" in Total Claims is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid For" in (Independent Claims) is less than 3, write "3" in this space.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. 1.16 which may be required by this paper or credit any overpayment to Account No. 18-1982. Two duplicate copies of this paper are enclosed.

Respectfully submitted,

Joseph D. Rossi
 Joseph D. Rossi, Registration No. 47,038
 Attorney for Applicant

Aventis Pharmaceuticals Inc.
 Patent Department
 Route #202-206 / P.O. Box 6800
 Bridgewater, New Jersey 08807-0800
 Telephone (908) 231-3410
 Telefax (908) 231-2626
 Aventis Docket No. USA2797 US CNT